The FDA has approved Halozyme Therapeutics' Hylenex recombinant (hyaluronidase human injection) for use as an adjuvant agent to increase the absorption and dispersion of other injected drugs. "We are thrilled that the FDA has approved our first NDA filing," said Jonathan Lim, M.D., Halozyme's chairman and CEO.
- read this press release for more information